



Pentokey Organy (India) Limited

Date: 27th January, 2024

BSE Limited
P J Tower
Dalal Street, Fort
Mumbai, 400 001

Subject: Outcome of Board Meeting of Pentokey Organy (India) Limited held on 27th January, 2024.

Reference: BSE Scrip Code: 524210

Madam/ Sir,

This is to inform you that pursuant to Regulation 30 & Regulation 33 of Securities Exchange Board of India (Listing Obligation and Disclosure requirement) Regulation 2015 "Listing regulation" and other applicable provisions, the Board of Directors of the company at its meeting held today have:

Approved Unaudited Financial Results of the Company for the quarter and nine months ended 31st December, 2023.

A Copy of the Unaudited Financial Results along with Limited Review Reports thereon are enclosed herewith for your information and record.

Further, pursuant to Regulation 47(1)(b) of the SEBI Listing Regulations, the Company would be publishing extract of Unaudited Financial Results for the quarter and nine months ended 30th December, 2023.

The meeting of the Board of Directors of the Company commenced at 1.00 PM and concluded at 2.15 P.M.

This is for your information and records.

For PENTOKEY ORGANY (INDIA) LIMITED

Divya Desai
Company Seceretary



CIN: L24116MH1986PLC041681

Reg. Office: 509, Western Edge I, Western Express Highway, Borivali(East), Mumbai- 400 066
Phone: +91-22-28545118 / 28545119 www.pentokey.com



Pentokey Organy (India) Limited

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31st DECEMBER, 2023

(Rs. in Lakh)

Particulars	Quarter Ended	Quarter Ended	Quarter Ended	Nine Months Ended	Nine Month Ended	Year Ended
	31.12.2023	30.09.2023	31.12.2022	31.12.2023	31.12.2022	31.03.2023
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I Revenue from Operations	3.31	206.78	232.13	439.63	375.77	436.55
II Other Income	10.71	11.29	212.20	33.19	224.91	235.60
III Total Income (I+II)	14.02	218.07	444.33	472.82	600.68	672.15
IV Expenses						
a) Purchase of Stock-in-trade / Cost of Materials Sold	0.28	63.17	148.45	324.56	276.51	341.38
b) Change in inventories of finished goods, work-in-progress and stock-in-trade	3.28	96.65	-	20.57	-	(20.57)
c) Employee benefits expenses	3.91	2.60	2.38	10.69	11.32	13.78
d) Finance costs	-	0.00	-	0.60	-	2.85
d) Depreciation and amortisation expense	0.07	0.07	0.09	0.22	0.30	0.39
e) Others Expenses	2.43	20.00	5.09	33.71	14.74	16.77
Total Expenses	9.97	182.50	156.01	390.35	302.87	354.60
V Profit / (Loss) before exceptional items and tax (III-IV)	4.05	35.57	288.32	82.47	297.81	317.55
VI Exceptional items - Profit / (Loss) on Sales of Property Plant & Equipments	-	-	-	-	-	-
VII Profit / (Loss) after exceptional items and tax (V+VI)	4.05	35.57	288.32	82.47	297.81	317.55
VIII Tax expense						
Current Tax	-	-	-	-	-	-
IX Profit / (Loss) for the period from continuing operations (VII-VIII)	4.05	35.57	288.32	82.47	297.81	317.55
X Other Comprehensive Income						
(i) Items that will not be reclassified to profit or loss	0.22	0.13	0.42	0.59	0.60	0.15
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
XI Total Comprehensive Income for the period (IX+ X)	4.27	35.70	288.74	83.06	298.41	317.70
XII Paid-up equity share capital	627.26	627.26	627.26	627.26	627.26	627.26
XIII Reserves excluding revaluation reserves	-	-	-	-	-	210.64
XIV Earnings per equity share (for continuing operations)						
1) Basic	0.06	0.57	4.60	1.31	4.75	5.06
2) Diluted	0.06	0.57	4.60	1.31	4.75	5.06

NOTES:

- The above results have been reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors in their meeting held on 27 January, 2024.
- The above financial results have been reviewed by the statutory Auditors of the company and they have issued an unmodified Limited Review Report of the same.
- The above results pertain to "Pharma Segment" which is the only business segment of the Company.
- The above results have been prepared in accordance with the Company's (Indian Accounting Standards), Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 read with the rules thereunder and other recognised accounting practices and policies to the extent applicable.
- 'Other Income in the Financial Results for the Nine Months ended 31.12.2022/ Year ended 31st March, 2023 includes Rs.200 Lakhs towards recovery of Bad Debts provided for earlier.
- Outstanding Income tax demand of Rs 171.58 for AY 2015-16 against which the company had preferred Appeal is yet pending.
- The figures for the previous year and corresponding periods have been regrouped, rearranged or recasted wherever necessary to conform to current period's presentation.

Place : Mumbai
Date : 27 January, 2024

For Pentokey Organy (India) Limited

Kostuv Kejriwal
Director
DIN : 00285687



Reg. Office: 509, Western Edge I, Western Express Highway, Borivali (East),
Mumbai - 400 066, India. Land Line +91-22-28545118 / 28545119

Branch Office: 403, 4th Floor, Liberty Chambers, Near LIC Office, Rishikesh Triveni Road,
Nannura Surat - 395001 Gujarat



VERMA MEHTA & ASSOCIATES

Chartered Accountants

104, Creative Industries Premises, Sunder Nagar, Kalina, Sanatcruz (East) Mumbai 400098
Tel : 2666 6359 Fax : 6693 5131 E- Mail - vmaca92@gmail.com

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

To The Board of Directors

Pentokey Organy (India) Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Pentokey Organy (India) Limited ("the Company"), for the Quarter and Nine months ended December 31, 2023 ("the Statement"), together with the relevant notes thereon (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations, 2015") read with SEBI circular dated July 5, 2016, which has been initialed by us for identification purposes. The Statement has been prepared in accordance with the recognition


and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.

3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data, and thus provide less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

Branch Office: Pune | Aurangabad | Ahmedabad | Vadodara | Mohali





VERMA MEHTA & ASSOCIATES

Chartered Accountants

104, Creative Industries Premises, Sunder Nagar, Kalina, Sanatcruz (East) Mumbai 400098
Tel : 2666 6359 Fax : 6693 5131 E- Mail - vmaca92@gmail.com

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with Ind AS and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015, read with SEBI circular dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement

For

M/s Verma Mehta & Associates

Chartered Accountants

Firm's Registration No: 112118W



CA Rohit Rahalkar

Partner

M.N. 139232

UDIN: 24139232 BKA 4TB 8684

Place: Mumbai

Date: 27/01/2024

Branch Office: Pune | Aurangabad | Ahmedabad | Vadodara | Mohali